Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Vibostolimab · MK-7684

Monoclonal antibody · Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT) · developed by Merck &

Phase 2 Most advanced trial (none active)
MRK Developer

What is Vibostolimab?

Vibostolimab is an antibody that binds TIGIT, an inhibitory receptor on tumor-infiltrating T lymphocytes and NK cells, and blocks its interaction with the ligands CD112 and CD155. This frees the costimulatory receptor CD226 to signal and activate anti-tumor T-cell and NK cell responses. It is studied in colorectal cancer, in co-formulation with pembrolizumab.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
MK-7684
Drug type
Monoclonal antibody
Targets
T-cell immunoreceptor with Ig and ITIM domains (TIGIT)
Mechanism
Inhibitor of T-cell immunoreceptor with Ig and ITIM domains (TIGIT)
Pathways
CD226 (DNAM-1) costimulatory signaling, T-cell and NK cell activation
Therapy area
Oncology
Developer
Merck & Co. (MRK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
5XO3JF0FEK

Conditions studied

Colorectal Cancer

Other drugs acting on TIGIT

More from Merck &

Sources

Updated Nov 15, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Vibostolimab

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.